Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma

Martha Lacy, Angela Dispenzieri, Morie Gertz, Philip R. Greipp, Kimberly L. Gollbach, Suzanne R. Hayman, Shaji K Kumar, John A. Lust, S Vincent Rajkumar, Stephen J Russell, Thomas Elmer Witzig, Steven R. Zeldenrust, David M Dingli, Peter Leif Bergsagel, Rafael Fonseca, Craig B. Reeder, Alexander Keith Stewart, Vivek Roy, Robert J. Dalton, Alan B. CarrDeepak Kademani, Eugene E. Keller, Christopher F. Viozzi, Robert A. Kyle

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

Bisphosphonates are effective in the prevention and treatment of bone disease in multiple myeloma (MM). Osteonecrosis of the jaw is Increasingly recognized as a serious complication of long-term bisphosphonate therapy. Issues such as the choice of blsphosphonate and duration of therapy have become the subject of intense debate given patient safety concerns. We reviewed available data concerning the use of bisphosphonates in MM. Guidelines for the use of bisphosphonates in MM were developed by a multidisciplinary panel consisting of hematologists, dental specialists, and nurses specializing in the treatment of MM. We conclude that intravenous pamidronate and intravenous zoledronic acid are equally effective and superior to placebo in reducing skeletal complications. Pamidronate is favored over zoledronic acid until more data are available on the risk of complications (osteonecrosis of the jaw). We recommend discontinuing bisphosphonates after 2 years of therapy for patients who achieve complete response and/or plateau phase. For patients whose disease is active, who have not achieved a response, or who have threatening bone disease beyond 2 years, therapy can be decreased to every 3 months. These guidelines were developed in the interest of patient safety and will be reexamined as new data emerge regarding risks and benefits.

Original languageEnglish (US)
Pages (from-to)1047-1053
Number of pages7
JournalMayo Clinic Proceedings
Volume81
Issue number8
DOIs
StatePublished - 2006

Fingerprint

Diphosphonates
Multiple Myeloma
pamidronate
zoledronic acid
Osteonecrosis
Bone Diseases
Patient Safety
Jaw
Therapeutics
Guidelines
Dental Assistants
Placebos

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. / Lacy, Martha; Dispenzieri, Angela; Gertz, Morie; Greipp, Philip R.; Gollbach, Kimberly L.; Hayman, Suzanne R.; Kumar, Shaji K; Lust, John A.; Rajkumar, S Vincent; Russell, Stephen J; Witzig, Thomas Elmer; Zeldenrust, Steven R.; Dingli, David M; Bergsagel, Peter Leif; Fonseca, Rafael; Reeder, Craig B.; Stewart, Alexander Keith; Roy, Vivek; Dalton, Robert J.; Carr, Alan B.; Kademani, Deepak; Keller, Eugene E.; Viozzi, Christopher F.; Kyle, Robert A.

In: Mayo Clinic Proceedings, Vol. 81, No. 8, 2006, p. 1047-1053.

Research output: Contribution to journalArticle

Lacy, M, Dispenzieri, A, Gertz, M, Greipp, PR, Gollbach, KL, Hayman, SR, Kumar, SK, Lust, JA, Rajkumar, SV, Russell, SJ, Witzig, TE, Zeldenrust, SR, Dingli, DM, Bergsagel, PL, Fonseca, R, Reeder, CB, Stewart, AK, Roy, V, Dalton, RJ, Carr, AB, Kademani, D, Keller, EE, Viozzi, CF & Kyle, RA 2006, 'Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma', Mayo Clinic Proceedings, vol. 81, no. 8, pp. 1047-1053. https://doi.org/10.4065/81.8.1047
Lacy, Martha ; Dispenzieri, Angela ; Gertz, Morie ; Greipp, Philip R. ; Gollbach, Kimberly L. ; Hayman, Suzanne R. ; Kumar, Shaji K ; Lust, John A. ; Rajkumar, S Vincent ; Russell, Stephen J ; Witzig, Thomas Elmer ; Zeldenrust, Steven R. ; Dingli, David M ; Bergsagel, Peter Leif ; Fonseca, Rafael ; Reeder, Craig B. ; Stewart, Alexander Keith ; Roy, Vivek ; Dalton, Robert J. ; Carr, Alan B. ; Kademani, Deepak ; Keller, Eugene E. ; Viozzi, Christopher F. ; Kyle, Robert A. / Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. In: Mayo Clinic Proceedings. 2006 ; Vol. 81, No. 8. pp. 1047-1053.
@article{98b9bb39f8004b999ec106bc81b317c8,
title = "Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma",
abstract = "Bisphosphonates are effective in the prevention and treatment of bone disease in multiple myeloma (MM). Osteonecrosis of the jaw is Increasingly recognized as a serious complication of long-term bisphosphonate therapy. Issues such as the choice of blsphosphonate and duration of therapy have become the subject of intense debate given patient safety concerns. We reviewed available data concerning the use of bisphosphonates in MM. Guidelines for the use of bisphosphonates in MM were developed by a multidisciplinary panel consisting of hematologists, dental specialists, and nurses specializing in the treatment of MM. We conclude that intravenous pamidronate and intravenous zoledronic acid are equally effective and superior to placebo in reducing skeletal complications. Pamidronate is favored over zoledronic acid until more data are available on the risk of complications (osteonecrosis of the jaw). We recommend discontinuing bisphosphonates after 2 years of therapy for patients who achieve complete response and/or plateau phase. For patients whose disease is active, who have not achieved a response, or who have threatening bone disease beyond 2 years, therapy can be decreased to every 3 months. These guidelines were developed in the interest of patient safety and will be reexamined as new data emerge regarding risks and benefits.",
author = "Martha Lacy and Angela Dispenzieri and Morie Gertz and Greipp, {Philip R.} and Gollbach, {Kimberly L.} and Hayman, {Suzanne R.} and Kumar, {Shaji K} and Lust, {John A.} and Rajkumar, {S Vincent} and Russell, {Stephen J} and Witzig, {Thomas Elmer} and Zeldenrust, {Steven R.} and Dingli, {David M} and Bergsagel, {Peter Leif} and Rafael Fonseca and Reeder, {Craig B.} and Stewart, {Alexander Keith} and Vivek Roy and Dalton, {Robert J.} and Carr, {Alan B.} and Deepak Kademani and Keller, {Eugene E.} and Viozzi, {Christopher F.} and Kyle, {Robert A.}",
year = "2006",
doi = "10.4065/81.8.1047",
language = "English (US)",
volume = "81",
pages = "1047--1053",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",

}

TY - JOUR

T1 - Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Gertz, Morie

AU - Greipp, Philip R.

AU - Gollbach, Kimberly L.

AU - Hayman, Suzanne R.

AU - Kumar, Shaji K

AU - Lust, John A.

AU - Rajkumar, S Vincent

AU - Russell, Stephen J

AU - Witzig, Thomas Elmer

AU - Zeldenrust, Steven R.

AU - Dingli, David M

AU - Bergsagel, Peter Leif

AU - Fonseca, Rafael

AU - Reeder, Craig B.

AU - Stewart, Alexander Keith

AU - Roy, Vivek

AU - Dalton, Robert J.

AU - Carr, Alan B.

AU - Kademani, Deepak

AU - Keller, Eugene E.

AU - Viozzi, Christopher F.

AU - Kyle, Robert A.

PY - 2006

Y1 - 2006

N2 - Bisphosphonates are effective in the prevention and treatment of bone disease in multiple myeloma (MM). Osteonecrosis of the jaw is Increasingly recognized as a serious complication of long-term bisphosphonate therapy. Issues such as the choice of blsphosphonate and duration of therapy have become the subject of intense debate given patient safety concerns. We reviewed available data concerning the use of bisphosphonates in MM. Guidelines for the use of bisphosphonates in MM were developed by a multidisciplinary panel consisting of hematologists, dental specialists, and nurses specializing in the treatment of MM. We conclude that intravenous pamidronate and intravenous zoledronic acid are equally effective and superior to placebo in reducing skeletal complications. Pamidronate is favored over zoledronic acid until more data are available on the risk of complications (osteonecrosis of the jaw). We recommend discontinuing bisphosphonates after 2 years of therapy for patients who achieve complete response and/or plateau phase. For patients whose disease is active, who have not achieved a response, or who have threatening bone disease beyond 2 years, therapy can be decreased to every 3 months. These guidelines were developed in the interest of patient safety and will be reexamined as new data emerge regarding risks and benefits.

AB - Bisphosphonates are effective in the prevention and treatment of bone disease in multiple myeloma (MM). Osteonecrosis of the jaw is Increasingly recognized as a serious complication of long-term bisphosphonate therapy. Issues such as the choice of blsphosphonate and duration of therapy have become the subject of intense debate given patient safety concerns. We reviewed available data concerning the use of bisphosphonates in MM. Guidelines for the use of bisphosphonates in MM were developed by a multidisciplinary panel consisting of hematologists, dental specialists, and nurses specializing in the treatment of MM. We conclude that intravenous pamidronate and intravenous zoledronic acid are equally effective and superior to placebo in reducing skeletal complications. Pamidronate is favored over zoledronic acid until more data are available on the risk of complications (osteonecrosis of the jaw). We recommend discontinuing bisphosphonates after 2 years of therapy for patients who achieve complete response and/or plateau phase. For patients whose disease is active, who have not achieved a response, or who have threatening bone disease beyond 2 years, therapy can be decreased to every 3 months. These guidelines were developed in the interest of patient safety and will be reexamined as new data emerge regarding risks and benefits.

UR - http://www.scopus.com/inward/record.url?scp=33746855407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746855407&partnerID=8YFLogxK

U2 - 10.4065/81.8.1047

DO - 10.4065/81.8.1047

M3 - Article

C2 - 16901028

AN - SCOPUS:33746855407

VL - 81

SP - 1047

EP - 1053

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 8

ER -